Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk by Brook, Robert D et al.
1536  Brook RD, et al. Heart 2017;103:1536–1542. doi:10.1136/heartjnl-2016-310897
AbstrAct
Objectives Cardiovascular disease (CVD) and chronic 
obstructive pulmonary disease (COPD) often coexist. 
We assessed the effect of inhaled COPD treatments on 
CVD outcomes and safety in patients with COPD and at 
heightened CVD risk.
Methods The SUMMIT (Study to Understand Mortality 
and MorbidITy) was a multicentre, randomised, double-
blind, placebo-controlled, event-driven trial in 16 485 
patients with moderate COPD who had or were at high 
risk of CVD. Here, we assessed the prespecified secondary 
endpoint of time to first on-treatment composite CVD event 
(CVD death, myocardial infarction, stroke, unstable angina 
or transient ischaemic attack (TIA)) by Cox regression and 
by clinician-reported CVD adverse events across the four 
groups: once-daily inhaled placebo (n=4111), long-acting 
beta2-agonist (vilanterol (VI) 25 µg; n=4118), corticosteroid 
(fluticasone furoate (FF) 100 µg; n=4135) and combination 
therapy (FF/VI; n=4121).
results Participants were predominantly middle-aged 
(mean 65 (SD 8) years) men (75%) with overt CVD 
(66%). The composite CVD endpoint occurred in 688 
patients (first event: sudden death (35%), acute coronary 
syndrome (37%) and stroke or TIA (23%), and was not 
reduced in any treatment group versus placebo: VI (HR 
0.99, 95% CI 0.80 to 1.22), FF (HR 0.90, 95% CI 0.72 
to 1.11) and their combination (HR 0.93, 95% CI 0.75 
to 1.14). Outcomes were similar among all subgroups. 
Adverse events, including palpitations and arrhythmias, 
did not differ by treatment.
conclusions In patients with COPD with moderate 
airflow limitation and heightened CVD risk, treatment 
with inhaled VI, FF or their combination has an excellent 
safety profile and does not impact CVD outcomes.
trial registration number NCT01313676.
IntrOductIOn
Cardiovascular disease (CVD), comprising both 
coronary heart disease and strokes, in conjunc-
tion with chronic obstructive pulmonary disease 
(COPD), accounts for the top three leading causes 
of death worldwide.1 Not only are they preva-
lent in the population, there is a well-established 
overlap of these conditions where CVD and COPD 
frequently coexist within individuals.2–5 Patients 
with COPD are more likely to have CVD than the 
general public.2–5 Roughly one-third of all deaths 
in those with COPD are due to CVD causes and 
the prognosis following a myocardial infarction 
(MI) is substantively worse in those with concomi-
tant COPD.6–8 While a growing number of studies 
have helped to explain these observations,9 10 the 
optimal management of patients diagnosed with 
both illnesses continues to be a matter of debate.11
One important issue contributing to present-day 
clinical equipoise is the unclear safety versus benefit 
of inhaled therapies for COPD in patients with 
coexisting CVD.11 Early studies and meta-anal-
yses gave rise to the long-standing contention that 
beta2-agonists heighten the risk for cardiovascular 
(CV) events.12 An analysis of a large healthcare 
database suggested that new usage of a long-acting 
beta2-agonist (LABA) was associated with a 31% 
increase in CV events among the elderly.13 This was 
not considered surprising given the mechanisms of 
action and potential side effects (eg, elevated heart 
rate) of LABAs.12 On the other hand, a post hoc 
analysis of the TORCH (Towards a Revolution in 
COPD Health) trial reported that salmeterol used 
alone or in combination with an inhaled cortico-
steroid (ICS) did not increase CVD events among 
patients with moderate to severe COPD.6 In fact, 
combination therapy was associated with a 17% 
lower risk of all CVD adverse events compared 
with placebo, and there was no excess CV risk in 
the small number of patients with a prior history of 
MI. These findings have been supported by a recent 
meta-analysis, which also suggested that treatment 
with a LABA actually decreases fatal CVD events.14 
While these results are encouraging, they do not 
resolve the debate given that most participants 
enrolled in prior clinical trials were likely at lower 
CVD risk than real-world patients with COPD.11 
In this context, the SUMMIT (Study to Under-
stand Mortality and MorbidITy) in COPD trial was 
designed to investigate the health effects of an ICS, 
a LABA, as well as their combination, specifically 
among patients with moderate COPD who had or 
were at high risk for CVD.15 The primary endpoint 
(all-cause mortality) was not significantly affected 
by combination therapy (HR 0.88, 95% CI 0.74 to 
1.04; p=0.14) although a secondary endpoint (rate 
of decline in postbronchodilator forced expiratory 
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volume in 1 s (FEV1)) was reduced.
16 Here, we present the 
detailed results regarding the other prespecified secondary 
endpoint of CVD events as well as the cardiac safety profile of 
the individual treatments.
MethOds
SUMMIT was a prospective, double-blind, parallel-group, place-
bo-controlled, event-driven (1000 deaths from any cause), 
randomised trial conducted at 1368 centres in 43 countries. 
Details regarding the trial design and primary results have been 
previously published.15 16 In brief, eligible participants included 
current or former smokers (≥10 pack-years) between the ages of 
40 and 80 years, with a history of COPD and a postbronchodilator 
FEV1 ≥50 and ≤70% of the predicted value, a ratio of postbron-
chodilator FEV1 to forced vital capacity ≤0.70, and a score ≥2 
on the modified Medical Research Council dyspnea scale. Patients 
were additionally required to have a history, or be at increased 
risk, of CVD. CVD was defined as coronary artery disease, periph-
eral arterial disease, prior stroke or MI, or diabetes mellitus with 
target organ disease.15 Increased CV risk was defined as being 
≥60 years plus receiving medications for two or more of the 
following: hypercholesterolaemia, hypertension, diabetes mellitus 
or peripheral vascular disease. While ICS and LABA treatments 
were discontinued before study entry, other COPD medications 
were permitted during the trial. Participants were then allocated 
equally to one of four randomised treatments: placebo, fluticasone 
furoate (FF, 100 µg), vilanterol (VI, 25 µg) or their combination 
(FF/VI, 100/25 µg) inhaled once daily as a dry powder. A total of 
16 485 patients were enrolled and included in the final intent-to-
treat (ITT) efficacy population.
In addition to the primary outcome of all-cause mortality by ITT 
analysis, a prespecified secondary composite CV efficacy endpoint 
(CV death, MI, stroke, unstable angina and transient ischaemic 
attack (TIA)) was also evaluated for patients on study treat-
ment. Categorisation of the cause of each death was adjudicated 
by a clinical endpoint committee who also adjudicated whether 
any reported CVD event met the definition of the secondary 
endpoint.15 Individuals discontinuing study treatments, who 
remained in the primary ITT analysis, could not be assessed for 
the adjudicated secondary CV endpoints as follow-up visits were 
not performed and only data regarding mortality were available. 
Adverse events were also reviewed at each study visit by the study 
investigators and coded using the Medical Dictionary for Regu-
latory Activities (MedDRA version 18.0; International Federation 
of Pharmaceutical Manufacturers and Associations, Geneva, Swit-
zerland). Adverse events of special interest are those associated 
with the known pharmacological action of a medication (eg, ICS 
or LABA therapy). For CV adverse events, Standardised MedDRA 
Queries are available for specific adverse events of special interest. 
These are predefined MedDRA-derived lists of preferred terms 
that allow a comprehensive review of safety data not limited to a 
specific preferred term.
To control for multiplicity of testing, a closed testing procedure 
(gatekeeper) approach was used. The hierarchy was the primary 
endpoint followed by the rate of decline in FEV1, followed by the 
composite CV endpoint. Since significance at the 5% level was 
not achieved for the primary endpoint, tests for the composite 
CV endpoint were interpreted as descriptive only. Kaplan-Meier 
graphs were produced, comparing the time to between-treat-
ment groups, for both the reported and adjudicated CVD events. 
Details of CVD events were tabulated by treatment group. A Cox 
proportional hazards regression model was used to analyse the 
time to the first adjudicated on-treatment composite CV event, 
with the covariates of age, sex, an indicator for ischaemic heart 
disease (previous MI or previous coronary revascularisation of 
any type) and an indicator for vascular disease (previous TIA, 
stroke, arterial bruits, or medication and/or surgery for carotid 
or aortofemoral arterial disease). Patients were divided into a 
number of subgroups, and a comparison of the time to first CVD 
event for patients on treatment with combination therapy versus 
placebo was performed using a separate Cox model for each 
subgroup, and the results presented in a forest plot.
results
Safety information was collected from 16 568 patients who were 
randomised and took study medication. Five centres were closed 
before the study ended because of failure to meet the standards 
of Good Clinical Practice and ethical practice, and data from 
their 83 patients were excluded from the efficacy analysis. Thus, 
a total of 16 485 patients were included in the ITT population 
(table 1). The study patients were predominately middle-aged 
white men, with roughly half remaining active smokers. Mean 
screening blood pressure levels were controlled and more than 
half of all patients were receiving antiplatelet agents, statins and 
renin–angiotensin system inhibitors. A total of 182 patients did 
not meet CV entry criteria but were included in both primary 
and secondary analyses. Among all participants in the efficacy 
analysis, 3535 (21%) were ≥40 and <60 years with CVD, 8127 
(49%) were ≥60 years with CVD, and 4641 (28%) were ≥60 
years old with increased CV risk only (ie, no prior history of 
CVD). By our prespecified definition, 11 662 (71%) patients had 
CVD. Excluding those with diabetes plus target organ disease 
(n=701) from this definition yields 10 961 (66%) patients who 
had ‘overt’ CVD (eg, prior MI).
Adjudicated cV outcomes
The composite CVD endpoint occurred in 688 patients; for 240 
(35%) patients the first event was sudden death, for 256 patients 
(37%) it was acute coronary syndrome, and for 161 patients 
(23%) it was stroke or TIA. The proportions of patients with an 
on-treatment composite CV endpoint as well as the individual 
component events were similar across treatment groups (table 2). 
Combination therapy had no effect on the time to first composite 
CV endpoint compared with placebo (HR 0.93, 95% CI 0.75 to 
1.14; p=0.48) (figure 1). Similarly, time to first composite CV 
endpoint in the FF (HR 0.90, 95% CI 0.72 to 1.11; p=0.32) 
and VI (HR 0.99, 95% CI 0.80 to 1.22; p=0.91) groups did 
not differ from placebo (figure 2). There was no evidence for 
differences in the HRs for the composite CV outcome among 
subgroups of patients on treatment with combination therapy 
versus placebo, in particular, between those patients with CVD 
compared with those with only CV risk (figure 3).
cV safety parameters
The proportion of participants on treatment reporting any 
adverse CVD event of special interest during the trial was similar 
among all groups: placebo (17%), FF (17%), VI (17%) and 
combination therapy (18%). Reported incidence of arrhythmia 
(5%, 6%, 5%, 5%), hypertension (5%, 5%, 5%, 6%), cardiac 
failure (5%, 4%, 4%, 5%), ischaemic heart disease (4%, 4%, 
4%, 4%) and any cerebrovascular (2%, 2%, 2%, 2%) adverse 
events was also similar across placebo, FF, VI and combina-
tion treatment, respectively. Serious adverse CVD events of 
special interest were reported in 8% of all groups. Full details 
of the adverse and serious adverse CVD events are presented in 
online supplementary tables 1 and 2. The time to first reported 
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on-treatment adverse CVD event of special interest did not differ 
among treatment groups (figure 4).
dIscussIOn
The safety and efficacy of inhaled therapies for COPD, espe-
cially LABAs, among patients with heightened CV risk has been 
a long-standing concern.11–13 These findings from SUMMIT 
provide much needed clinical trial evidence that an inhaled 
LABA (VI), ICS (FF) and their combination pose no excess 
CV risks. There were no significant treatment effects on the 
prespecified secondary composite CV endpoint. Although the 
original hypothesis was that combination therapy would reduce 
CVD events compared with placebo, the null results taken in 
conjunction with the overall favourable safety data support the 
contention that these inhaled therapies can be safely prescribed 
as clinically indicated to treat moderate COPD even in patients 
with, or at high risk for, CVD.
relationship between cOPd and cVd
Patients with COPD are much more likely to have, and die from, 
underlying CVD than the general population.2–5 Shared risk factors 
(eg, smoking, advanced age), overlapping biological pathways 
(eg, systemic inflammation, autonomic imbalance) and common 
genetic predispositions may help explain part of the association 
between COPD and CVD. Acute exacerbations of COPD per se 
(eg, hypoxia, stress) and delays in the diagnosis and management 
of acute coronary syndromes (eg, difficulties in differentiating 
the cause of chest pain) may play added roles in explaining the 
table 1 Screening characteristics of study participants
Placebo,
n=4111
Fluticasone furoate,
n=4135
Vilanterol,
n=4118
combination therapy,
n=4121
total,
n=16 485
Age, years 65 (8) 65 (8) 65 (8) 65 (8) 65 (8)
Female 1040 (25%)* 1082 (26%) 1065 (26%) 1009 (24%) 4196 (25%)
Race
  White 3328 (81%) 3358 (81%) 3339 (81%) 3332 (81%) 13 357 (81%)
  Asian 682 (17%) 683 (17%) 680 (17%) 679 (16%) 2724 (17%)
  Other 101 (2%) 94 (2%) 99 (2%) 110 (3%) 404 (2%)
Body mass index, kg/m2 28 (6) 28 (6) 28 (6) 28 (6) 28 (6)
Current smokers 1936 (47%) 1945 (47%) 1929 (47%) 1868 (45%) 7678 (47%)
Systolic blood pressure, mm Hg 135 (15) 135 (15) 135 (15) 135 (15) 135 (15)
Diastolic blood pressure, mm Hg 81 (10) 80 (10) 80 (10) 81 (10) 80 (10)
Heart rate, beats/min 76 (10) 76 (10) 76 (10) 76 (10) 76 (10)
Cardiovascular inclusion criteria†
  Cardiovascular disease
  Coronary artery disease 2103 (51%) 2119 (51%) 2044 (50%) 2113 (51%) 8379 (51%)
  Peripheral arterial disease 766 (19%) 755 (18%) 817 (20%) 807 (20%) 3145 (19%)
  Previous stroke 404 (10%) 418 (10%) 387 (9%) 386 (9%) 1595 (10%)
  Previous myocardial infarction 658 (16%) 664 (16%) 722 (18%) 730 (18%) 2774 (17%)
  Diabetes with target organ disease‡ 374 (9%) 355 (9%) 377 (9%) 397 (10%) 1503 (9%)
High risk (receiving treatment for):
  Hypercholesterolaemia 2112 (51%) 2051 (50%) 2191 (53%) 2125 (52%) 8479 (51%)
  Hypertension 2861 (70%) 2835 (69%) 2900 (70%) 2882 (70%) 11 478 (70%)
  Diabetes mellitus 850 (21%) 870 (21%) 874 (21%) 886 (21%) 3480 (21%)
  Peripheral arterial disease 279 (7%) 264 (6%) 301 (7%) 310 (8%) 1154 (7%)
Concomitant cardiovascular therapy (taken >30 days)
  Any medication 3996 (97%) 4009 (97%) 3996 (97%) 4021 (98%) 16 022 (97%)
  Antithrombotic/coagulant 2292 (56%) 2316 (56%) 2295 (56%) 2384 (58%) 9287 (56%)
  Antiplatelet therapy§ 2101 (51%) 2123 (51%) 2093 (51%) 2200 (53%) 8517 (52%)
  Lipid-lowering medication 2751 (67%) 2746 (66%) 2797 (68%) 2829 (69%) 11 123 (67%)
  Statin 2647 (64%) 2652 (64%) 2693 (65%) 2729 (66%) 10 721 (65%)
  RAS-aldosterone inhibitor¶ 2887 (70%) 2841 (69%) 2862 (69%) 2932 (71%) 11 522 (70%)
  Beta-blockers 1389 (34%) 1458 (35%) 1376 (33%) 1444 (35%) 5667 (34%)
  Beta1 selective 1151 (28%) 1205 (29%) 1141 (28%) 1166 (28%) 4663 (28%)
  Calcium channel blockers 1551 (38%) 1606 (39%) 1569 (38%) 1593 (39%) 6319 (38%)
  Dihydropyridine 1188 (29%) 1258 (30%) 1206 (29%) 1222 (30%) 4874 (30%)
  Long-acting or short-acting nitrates 613 (15%) 556 (13%) 569 (14%) 556 (13%) 2294 (14%)
  Diuretics** 1508 (37%) 1541 (37%) 1549 (38%) 1550 (38%) 6148 (37%)
Age, body mass index, blood pressure and heart rate are given in mean (SD). 
*Represents the percentage of all patients within the individual treatment group.
†Patients can have multiple cardiovascular diseases or risks at study entry.
‡Target organ disease: diagnosed nephropathy, retinopathy or neuropathy.
§Monotherapy or combination therapy with aspirin, P2Y12 receptor antagonist, other antiplatelet agent.
¶Monotherapy or combination therapy with ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor blockers, direct renin inhibitors.
**Monotherapy or combination therapy with thiazide, thiazide-like, loop or other diuretic.
RAS, renin–angiotensin system.
1539Brook RD, et al. Heart 2017;103:1536–1542. doi:10.1136/heartjnl-2016-310897
Pulmonary vascular disease
heightened CVD risk of patients with both diseases.7–9 It has also 
been a long-standing contention that the inhaled therapies for 
COPD themselves may further potentiate CV events.11–13
Although few studies have evaluated the CVD safety of 
ICS therapy, many short-term trials12 and large administrative 
datasets13 have raised concerns regarding possible harm of LABA 
treatment. Even a ‘highly selective’ beta2-receptor agonist could 
be detrimental to susceptible patients through chronotropic and 
proarrhythmic actions.10 11 On the other hand, the TORCH 
study provided some of the first clues that LABA treatment is 
safe and might actually reduce CVD events in some patients.6 
These observations have also been supported by a recent 
meta-analysis.14 Our findings from SUMMIT provide some of 
the most robust clinical trial evidence to date that an ICS (FF), 
LABA (VI) and their combination appear to be safe, even among 
patients with, or at high risk for, CVD. There was no evidence 
to support benefit or harm on the secondary composite CV 
outcome, nor did a wide array of safety parameters differ among 
the various treatment groups. We interpret these results to indi-
cate that healthcare providers should be reassured about treating 
patients for COPD as clinically indicated (ie, to reduce exacerba-
tions) even if they are also at heightened CVD risk. Since this is 
a common scenario due to the highly prevalent overlap between 
CVD and COPD, our findings are of key clinical relevance.
strengths and limitations
This is the first COPD outcome trial to specifically enrol patients 
with, or at heightened risk for, CVD. This is also the first trial 
to include a prespecified secondary outcome of composite CVD 
events among such patients. The primary SUMMIT publica-
tion presented only the main trial results.16 This current report 
significantly adds to the literature as here we present the full 
details in regard to all CVD outcomes (a prespecified secondary 
outcome) and safety data. Given high prevalence and overlap of 
CVD and COPD in the population,2–6 a thorough understanding 
of the risks and benefits of treating COPD with inhaled therapies 
is of major clinical importance.10 11
Since the trial did not meet its primary endpoint (all-cause 
mortality) of superiority, the secondary composite CV results must 
be correctly interpreted as descriptive or hypothesis generating. 
An a priori hypothesis of ‘non-inferiority’ of the treatments versus 
placebo may have provided even further reassurance of their safety 
table 2 Number of patients with adjudicated cardiovascular events 
in treatment groups*
On-treatment 
adjudicated first 
cardiovascular event
Placebo
n=4111
Fluticasone 
furoate
n=4135
Vilanterol
n=4118
combination 
therapy
n=4121
Patients with composite 
cardiovascular outcome
173 (4.2%) 161 (3.9%) 180 (4.4%) 174 (4.2%)
Myocardial infarction† 38 (0.9%) 45 (1.1%) 44 (1.1%) 46 (1.1%)
  Type 1 33 38 36 39
  Type 2 5 6 3 6
  Other/indeterminate 0 1 5 1
Unstable angina† 26 (0.6%) 16 (0.4%) 22 (0.5%) 19 (0.5%)
Stroke† 33 (0.8%) 33 (0.8%) 30 (0.7%) 31 (0.8%)
  Ischaemic 24 29 20 24
  Haemorrhagic 6 3 8 4
  Indeterminate 3 1 2 3
Transient ischaemic 
attack
8 (0.2%) 7 (0.2%) 12 (0.3%) 7 (0.2%)
Sudden death 62 (1.5%) 53 (1.3%) 62 (1.5%) 63 (1.5%)
Cardiac surgery death 1 (<0.1%) 1 (<0.1%) 0 0
Other cardiovascular 
death
5 (0.1%) 6 (0.1%) 10 (0.2%) 8 (0.2%)
  Heart failure 2 5 4 5
  Peripheral vascular 
disease
3 1 5 3
  Heart valve 0 0 1 0
Data are number of patients (%).
*There was no statistically significant difference in the number of patients with a 
composite cardiovascular event between treatment groups.
†Events may be fatal or non-fatal. Note that these are the first cardiovascular (CV) 
event—patients may have gone on to experience another CV event later.
Figure 1 Risks of adjudicated composite CV endpoints in patients treated with combination therapy versus placebo Kaplan-Meier graph for 
the time to first adjudicated on-treatment composite CVD event (CVD death, myocardial infarction, stroke, unstable angina or TIA) for patients on 
treatment with combination therapy (VI plus FF) versus placebo. CV, cardiovascular; CVD, cardiovascular disease; FF, fluticasone furoate; TIA, transient 
ischaemic attack; VI, vilanterol.
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Figure 2 Risks of adjudicated composite CV endpoints for all treatment groups. Kaplan-Meier graph for the time to first adjudicated on-treatment 
composite CVD event (CVD death, myocardial infarction, stroke, unstable angina or TIA) for patients on treatment with VI, FF, combination therapy 
and placebo. CV, cardiovascular; CVD, cardiovascular disease; FF, fluticasone furoate; TIA, transient ischaemic attack; VI, vilanterol.
Figure 3 Risks of adjudicated composite CV endpoints in subgroups treated with combination therapy versus placebo forest plot of the HRs and 
95% CIs for the adjudicated composite CV endpoint in subgroups of patients on treatment with combination therapy versus placebo. Cardiovascular 
entry criteria with CVD defined as at least one of the following: coronary artery disease, peripheral arterial disease, previous stroke, previous MI 
or diabetes mellitus with target organ disease. Regions are defined in online supplementary table 3. Ischaemic heart disease indicator defined as 
previous MI or previous revascularisation of any type; vascular disease indicator defined as previous TIA, stroke, arterial bruits, or medication and/
or surgery for carotid or aortofemoral vascular disease. ‘n’ represents number of patients in combined FF/VI and placebo arms shaded regions show 
overall 95% CI. CV, cardiovascular; CVD, cardiovascular disease; FF, fluticasone furoate; MI, myocardial infarction; TIA, transient ischaemic attack; VI, 
vilanterol.
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from a statistical standpoint. Whether these results represent a 
class effect applicable to other LABA, ICS or combination thera-
pies is currently unknown. It also remains unclear if these findings 
can be extrapolated to patients with more severe COPD or with 
additional high-risk cardiac conditions (eg, recent acute coronary 
syndrome, heart failure and arrhythmias). The CVD risks related to 
inhaled anticholinergic therapies were not evaluated by SUMMIT, 
and it also remains a contentious issue with mixed evidence.17–20 
Nevertheless, SUMMIT is one of the largest outcome trials where 
patients with COPD are at heightened CV risk and its findings are 
applicable to a number of patients who have concomitant CVD 
with COPD and as such its findings may help inform clinical deci-
sion making. The use of secondary preventive medicines including 
aspirin, beta blockers and statins (table 1) for the 66% of patients 
Figure 4 Risks of reported adverse cardiovascular events among treatment groups. Kaplan-Meier graph for time to first reported on-treatment 
(A) adverse and (B) serious adverse cardiac events of special interest in patients on treatment with VI, FF, combination therapy and placebo. 
Cardiovascular adverse events of special interest are defined as any untoward medical occurrence falling within Standardised MedDRA (Medical 
Dictionary for Regulatory Activities) Queries of cardiac arrhythmias, hypertension, cardiac failure, ischaemic heart disease, or central nervous system 
haemorrhages and cerebrovascular conditions. Details are provided in online supplementary table 1. Serious cardiovascular adverse events of special 
interest are defined as above as those that also result in death or are life threatening or require hospitalisation or result in disability. Details are 
provided in online supplementary table 2. FF, fluticasone furoate; VI, vilanterol.
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with overt CVD is overall reasonable and indeed matches or 
exceeds that observed in most real-world settings globally.21 To this 
point, the influence of risk factor control (eg, blood pressure level) 
and medication usage (eg, beta blockers) on the health outcomes 
and their interactions with the health effects induced by the inhaled 
therapies will be evaluated in future analyses of the SUMMIT trial 
data. Finally, the use of short-acting beta-agonist therapy, including 
as rescue inhalers, was not evaluated in this study and requires 
further investigation regarding its CV safety.
cOnclusIOns
Treatment of moderate COPD with an inhaled LABA (VI), ICS 
(FF) and their combination appears to be safe among patients at 
heightened CV risk. Healthcare providers should be more reas-
sured about prescribing evidence-based inhaler therapies as indi-
cated for the management of moderate COPD in people with, or 
at heightened risk of, CVD.
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Key messages
What is already known on this subject?
Patients with chronic obstructive pulmonary disease (COPD) 
commonly have or are at high risk for cardiovascular disease 
(CVD). Published studies supporting the safety of inhaled COPD 
treatments, particularly beta2-agonists, in such patients have 
reported mixed findings.
What might this study add?
We demonstrate in a prespecified secondary analysis of a large 
randomised double-blind clinical trial that once-daily usage of 
an inhaled long-acting beta-agonist, corticosteroid and their 
combination is safe and significantly impacts CVD outcomes in 
patients with moderate COPD who have or are at high risk for CVD.
how might this impact on clinical practice?
These findings support that healthcare providers can be more 
reassured about prescribing these inhaled therapies as clinically 
indicated to treat moderate COPD even in patients at heightened 
CVD risk.
